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TREATMENTVERSUS ORALTREATMENT ALONE IN
MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS:
A DECISION-ANALYTIC MODEL
Nielsen SK1, Connolly MP1, Bhatt A1, Currie CJ2
1Ferring International Center, Saint-Prex, Switzerland,
2Cardiff University, Cardiff, UK
OBJECTIVES: The purpose of the study was to evaluate the
cost-effectiveness of concomitant oral plus enema mesalazine
therapy versus oral mesalazine alone in mild-to-moderate active
ulcerative colitis (UC). METHODS: Outcome data from a ran-
domised controlled, double-blind trial comparing mesalazine 4 g
oral plus 1 g enema (Oral + Enema) versus mesalazine 4 g oral
plus placebo enema (Oral-Alone) were used. A deterministic
decision-analytic model was constructed using trial and pub-
lished data sources. Two health states were considered in the
model: acute bleeding and remission. The base case evaluation
assessed costs and outcomes over the trial duration (8 weeks). A
second evaluation assessed cost and outcomes up to 26 weeks
taking into consideration additional treatment with steroids,
ciclosporin and surgery to achieve remission. The evaluation
perspective was that of the UK National Health Service and
cost data were derived from published sources. Health-related
quality of life data was extracted from the clinical trial to derive
quality adjusted life years (QALYs) for evaluation within the
model. Sensitivity analysis was carried out where appropriate.
RESULTS: Base case cost-effectiveness ratios were £9,813/QALY
for Oral + Enema and £9,708/QALY for Oral-Alone, with an
incremental cost per QALY of £14,094. At 8 weeks the incre-
mental cost difference was £44 for Oral + Enema, which was less
than the cost of enema therapy over the trial period, suggesting
that Oral + Enema results in cost-savings elsewhere in the health
system. At 26 weeks Oral + Enema was both cost-saving and
more efﬁcacious. The model suggests that adopting a
Oral + Enema treatment strategy in this population can save £82
per person. CONCLUSION: Oral + Enema treatment was more
cost-effective at 8 weeks than Oral-Alone based on accepted
cost-effectiveness thresholds in the UK of £20,000/QALY. At 26
weeks Oral + Enema therapy was cost-saving and more efﬁca-
cious compared with Oral-Alone because of improved remission
rates, which prevents UC patients from progressing to more
expensive interventions.
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INHIBITORS ON C & D ESOPHAGITISTREATMENT IN SPAIN
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OBJECTIVES: Determine which new generation proton pump
inhibitor (PPI) is most cost-effective in the maintenance phase
of patients with C & D esophagitis as well as their expected
impact on Spanish NHS budget. METHODS: A pharmacoeco-
nomic deterministic model, NHS perspective, was developed
to compare esomeprazole (ESO40 mg/d), lansoprazole
(LANSO30 mg/d) and pantoprazole (PANTO40 mg/d) in the
maintenance phase of patients with C&D esophaghitis. The
effectiveness measure considered was symptoms free-days after
12 months of treatment. And the costs included were drugs and
health care utilization resources (diagnostic methods, physicians
visits and surgery), expressed as 2006€. Moreover a budget
impact model was done to know the affordability of most cost-
effective drug utilization in a 1000 patients cohort. RESULTS:
ESO provide higher remission rates (308 days without symp-
toms) than the other alternatives: LANSO-231 days; PANTO-
270 days. The annual cost by patient are: 794€-ESO,
885€-LANSO, 772€-PANTO. The analysis indicates that ESO
being a dominant therapy vs. LANSO; and vs. PANTO presents
an incremental cost-effectiveness ratio of 0.59 €/day. The
expected cost by patient is 822.32€ (259 symptoms free-days),
based on 2006 treatment patterns. Increasing the ESO utilization
on 25, 50, 75 & 100%, instead of less effective and costly drugs,
could produce potential savings for the Spanish NHS: 1370€,
2850€, 4120€ & 6190€, respectively; which would allow treat-
ment of more patients with the same budget: 2, 3, 5 and 8
additional patients, correspondingly. CONCLUSION: ESO is the
most cost-effective and efﬁcient PPI in for treatment of patients
for the maintenance of C&D esophaghitis treatment in Spain.
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OBJECTIVES: To estimate the cost-effectiveness of treating
interferon-naïve CHC patients with peginterferon alfa-2a
(180 mcg/week) plus ribavirina (1200 mg/day) early before pro-
gression to more advanced disease. METHODS: A published
Markov lifetime model was used to estimate the costs and ben-
eﬁts associated with early versus delayed treatment for HCV. The
target population consisted of treatment-naive HCV-1 patients
with mild liver disease. The interventions were either early treat-
ment or regular monitoring (delayed treatment) for evidence of
progression to moderate or cirrhosis stage. Fibrosis progression
rates came from published longitudinal cohort studies. The
analysis was conducted from the perspective of the Italian NHS.
Life Years Gained (LYGs) were considered, as well as Quality-
Adjusted Life-Years (QALYs) and direct medical costs. LYGs and
QALYs were based on the results of an international clinical trial.
Beneﬁts and costs were discounted at 3%. Sensitivity analyses
were performed. RESULTS: Early treatment is expected to
reduce the risk of cirrhosis at 30 years by 13.5% (23.7% early vs.
37.2% delayed), to increase mean overall survival by 0.48 years
(29.77 LY early vs. 29.29 LY delayed) and to increase mean
survival adjusted for quality of life by 0.75 years (14.83 QALY
early vs. 14.08 QALY delayed). The expected cost (per patient) is
€27,313.26 with early treatment and €22,965.37 with regular
monitoring. The study calculated for early treatment versus
delayed treatment the incremental cost per life year gained and
per QALY gained. It was €9114.16 and €5823.92, respectively.
Sensitivity analyses showed that age and social discount rate are
the most inﬂuential parameters. CONCLUSION: Early treat-
ment with peginterferon alfa-2a (40KD) plus ribavirin of CHC
when this is at a mild stage is expected to reduce risk of cirrhosis,
to increase life expectancy, and to be cost-effective when com-
pared with monitoring for evidence and subsequent treatment of
advanced disease.
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COST-EFFECTIVENESS OF ESOMEPRAZOLE INTHE
TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX
OESOPHAGITIS
Borrill J, Edwards SJ
Astrazeneca UK Ltd, Luton, UK
OBJECTIVES: To evaluate the cost-effectiveness of esomeprazole
(40 mg once daily [od]) in adolescent patients with moderate or
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severe reﬂux oesophagitis (RO), Los Angeles grades C or D
compared with standard adult doses of other proton pump
inhibitors (PPIs), i.e., generic lansoprazole 30 mg od, generic
omeprazole 20 mg od, pantoprazole 40 mg od, and rabeprazole
20 mg od. METHODS: A simple decision-tree model was
designed to evaluate the cost-effectiveness of esomeprazole over a
6-month time horizon from the perspective of the UK National
Health Service. Healing rate probabilities were extrapolated
from the results of a meta-analysis of 6 randomised, controlled
trials that compared esomeprazole with other PPIs in adults who
had endoscopically-conﬁrmed RO. Data from the IMS Disease
Analyser was used to estimate the average duration of a course of
PPI therapy prescribed to adolescents in the UK. Health state
valuations were estimated from a European study that used Time
Trade Off to obtain utilities scores from a sample of more than
1,000 patients with GORD symptoms. RESULTS: Esomeprazole
was a cost-effective treatment option for adolescents with
moderate or severe RO versus all other standard-dose PPIs.
For example, incremental cost-effectiveness ratios ranged from
£2,200/QALY (95% CI, £1,100/QALY to £5,600/QALY) and
£15,200/QALY (95% CI, £6,700 to >£80,000/QALY), when
esomeprazole was compared with pantoprazole (in adolescents
with severe RO) and generic lansoprazole (in adolescents with
moderate RO), respectively. The probability of esomeprazole
being cost-effective at a threshold of £30,000/QALY was greater
than 84% for all the analyses that were undertaken. CONCLU-
SION: Esomeprazole is a cost-effective treatment for adolescent
patients who are presumed to have moderate or severe reﬂux
oesophagitis.
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OBJECTIVES: Determine which new generation proton pump
inhibitor (PPI) is most cost-effective in the treatment of GERD
after omeprazole failure as well as their expected impact on
Spanish NHS budget. METHODS: A pharmacoeconomic deter-
ministic model was developed, based on data extracted from
literature, form an NHS perspective to compare esomeprazole
(ESO40 mg/d), lansoprazole (LANSO30 mg/d), pantoprazole
(PANTO40 mg/d) and rabeprazole (RABE20 mg/d) in patients
with GERD refractory to omeprazole (patients without remission
or remaining symptomatic after OME 20 mg/day 4 weeks). The
effectiveness measure was symptom free-days after 12 months
of treatment. The costs included were drugs and health care
utilization resources (diagnostic methods, physicians visits and
surgery), expressed as 2006 €. Moreover a budget impact model
was done to know the affordability of most cost-effective drug
utilization in a 1000 patients cohort. RESULTS: ESO provide
higher remission rates (238 days without symptoms) than the
other alternatives: LANSO-213 days; PANTO-203 days; RABE-
205 days. The annual cost by patient are: 652€-ESO, 703€-
LANSO, 734€-PANTO; 706€-RABE. The analysis indicates that
ESO being a dominant therapy in this case. The expected cost by
patient is 428.84€ (310 symptoms free-days), based on 2006
treatment patterns. Increasing the ESO utilization on 25, 50, 75
& 100%, instead of less effective and costly drugs, could produce
potential savings for the Spanish NHS: 720€, 1430€, 2000€ &
2860€, respectively; which would allow for the treatment of
more patients with the same budget: 1.68, 3.35, 4.69 and 6.71
additional patients, correspondingly. CONCLUSION: ESO is the
most cost-effective and efﬁcient PPI in the treatment of GERD
after omeprazole failure in Spain.
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IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION
AND COSTS IN PATIENTS ON OPIOIDTHERAPY
Candrilli SD1, Iyer S2, Davis KL1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Wyeth
Research, Collegeville, PA, USA
OBJECTIVES: To assess the impact of constipation on opioid use
patterns, resource utilization, and costs in patients on opioid
therapy. METHODS: A retrospective study was conducted in
patients who initiated opioid therapy between 1/1/99 and 12/31/
05. Patients were identiﬁed from longitudinal insurance claims
from US health plans. An index date was deﬁned as the date of
the 1st pharmacy claim for an opioid. Patients had 30 days of
opioid use and continuous plan coverage for 6 months before
and 12 months after their index date. Outcomes were assessed
over 12 months following the index date. Constipation was
deﬁned as evidence of 1 ICD-9 code of 564.0 in the follow-up
period. Opioid use patterns were compared between patients
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